RVMD Revolution Medicines Inc

Price (delayed)

$46.77

Market cap

$7.72B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.82

Enterprise value

$7.51B

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities ...

Highlights
RVMD's quick ratio is up by 41% since the previous quarter and by 9% year-on-year
The company's equity has surged by 81% YoY but it fell by 6% QoQ
Revolution Medicines's net income has plunged by 87% YoY and by 11% from the previous quarter
The revenue has dropped by 87% year-on-year and by 61% since the previous quarter

Key stats

What are the main financial stats of RVMD
Market
Shares outstanding
164.99M
Market cap
$7.72B
Enterprise value
$7.51B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.46
Price to sales (P/S)
1,687.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,645.42
Earnings
Revenue
$4.57M
EBIT
-$487.49M
EBITDA
-$477.95M
Free cash flow
-$457.88M
Per share
EPS
-$3.82
Free cash flow per share
-$2.78
Book value per share
$10.48
Revenue per share
$0.03
TBVPS
$11.15
Balance sheet
Total assets
$1.91B
Total liabilities
$182.9M
Debt
$88.03M
Equity
$1.73B
Working capital
$1.64B
Liquidity
Debt to equity
0.05
Current ratio
18.45
Quick ratio
18.21
Net debt/EBITDA
0.43
Margins
EBITDA margin
-10,467.7%
Gross margin
100%
Net margin
-10,606%
Operating margin
-12,108.8%
Efficiency
Return on assets
-32.1%
Return on equity
-36.4%
Return on invested capital
-49.9%
Return on capital employed
-26.9%
Return on sales
-10,676.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RVMD stock price

How has the Revolution Medicines stock price performed over time
Intraday
-2.44%
1 week
0%
1 month
22.4%
1 year
74.71%
YTD
63.08%
QTD
20.51%

Financial performance

How have Revolution Medicines's revenue and profit performed over time
Revenue
$4.57M
Gross profit
$4.57M
Operating income
-$552.89M
Net income
-$484.27M
Gross margin
100%
Net margin
-10,606%
Revolution Medicines's operating margin has plunged by 188% from the previous quarter
The net margin has plunged by 181% from the previous quarter
RVMD's operating income has dropped by 101% year-on-year and by 13% since the previous quarter
Revolution Medicines's net income has plunged by 87% YoY and by 11% from the previous quarter

Growth

What is Revolution Medicines's growth rate over time

Valuation

What is Revolution Medicines stock price valuation
P/E
N/A
P/B
4.46
P/S
1,687.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,645.42
The EPS has declined by 26% year-on-year
The company's equity has surged by 81% YoY but it fell by 6% QoQ
The P/B is 54% higher than the last 4 quarters average of 2.9 and 31% higher than the 5-year quarterly average of 3.4
The revenue has dropped by 87% year-on-year and by 61% since the previous quarter

Efficiency

How efficient is Revolution Medicines business performance
The return on sales has dropped by 181% since the previous quarter
RVMD's ROIC is up by 16% since the previous quarter but it is down by 4.4% year-on-year
Revolution Medicines's return on equity has increased by 5% QoQ
RVMD's ROA is up by 4.5% QoQ but it is down by 3.5% YoY

Dividends

What is RVMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RVMD.

Financial health

How did Revolution Medicines financials performed over time
RVMD's total assets has soared by 78% year-on-year but it is down by 7% since the previous quarter
Revolution Medicines's total liabilities has soared by 51% YoY but it has decreased by 22% from the previous quarter
The debt is 95% less than the equity
The company's equity has surged by 81% YoY but it fell by 6% QoQ
The debt has grown by 38% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.